A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.
作者信息
Spyridonidis Alexandros, Liga Maria
机构信息
Hematology Division, BMT Unit, University Hospital of Patras 26500 Rio, Greece.
出版信息
Am J Blood Res. 2012;2(2):98-104. Epub 2012 May 18.
Abstract
The notion that immunocompetent cells, contained within adult bone marrow or peripheral blood, are capable of mediating an antitumor effect was first validated experimentally in 1957. T-cell immunotherapy for malignant disease is now routinely used in the context of allogeneic bone marrow transplantation. After 50 years of investigations into the use of T-cells for cancer therapy, adoptive cellular immunotherapy for cancer has progressed from the delivery of unspecific cellular products to the transfer of engineered tumor-specific T-cells. Adoptive cellular immunotherapy for cancer has now reached a stage of increasing feasibility and efficacy.
摘要
相似文献
1
A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.
Am J Blood Res. 2012;2(2):98-104. Epub 2012 May 18.
2
Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
Cancer Invest. 1992;10(1):19-26. doi: 10.3109/07357909209032785.
3
New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Bone Marrow Transplant. 2000 May;25 Suppl 2:S20-4. doi: 10.1038/sj.bmt.1702347.
4
Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.
J Natl Cancer Inst. 1995 Sep 6;87(17):1289-96. doi: 10.1093/jnci/87.17.1289.
5
Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
J Hematother Stem Cell Res. 2002 Apr;11(2):265-76. doi: 10.1089/152581602753658457.
6
Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Acta Microbiol Immunol Hung. 2010 Dec;57(4):253-347. doi: 10.1556/AMicr.57.2010.4.2.
7
Adoptive immunotherapy with donor lymphocyte transfusions.
Curr Opin Oncol. 1997 Mar;9(2):139-45. doi: 10.1097/00001622-199703000-00006.
8
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
N Engl J Med. 1995 Oct 19;333(16):1038-44. doi: 10.1056/NEJM199510193331603.
9
Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.
J Immunother. 1998 Nov;21(6):447-53. doi: 10.1097/00002371-199811000-00007.
10
Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy.
Hematology Am Soc Hematol Educ Program. 2000:356-375. doi: 10.1182/asheducation-2000.1.356.
本文引用的文献
1
Defining the critical hurdles in cancer immunotherapy.
J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.
2
Inducible apoptosis as a safety switch for adoptive cell therapy.
N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152.
3
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.
Blood. 2011 Nov 17;118(20):5681-8. doi: 10.1182/blood-2011-04-348805. Epub 2011 Sep 26.
4
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10.
5
CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia.
Bone Marrow Transplant. 2012 Mar;47(3):411-5. doi: 10.1038/bmt.2011.101. Epub 2011 May 9.
6
Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
Cytotherapy. 2011 May;13(5):516-7. doi: 10.3109/14653249.2011.561652. Epub 2011 Mar 7.
7
Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia.
Bone Marrow Transplant. 2011 Oct;46(10):1363-8. doi: 10.1038/bmt.2010.308. Epub 2010 Dec 20.
8
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
J Immunother. 2010 Apr;33(3):305-15. doi: 10.1097/CJI.0b013e3181c0c3cb.
9
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.
10
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
Bone Marrow Transplant. 2010 Apr;45(4):627-32. doi: 10.1038/bmt.2009.222. Epub 2009 Aug 31.
Zotero 插件